Oncopeptides AB is a Swedish pharmaceutical company specializing in developing innovative therapies for challenging hematological diseases. The company utilizes its unique Peptide Drug Conjugate (PDC) to create compounds that target cancer cells efficiently. With a Risk Rating Score of 29.6, Oncopeptides AB is categorized as a medium-risk company. Focus is on the development of Melflufen (Pepaxti), a peptide-conjugated alkylator designed to offer effective treatment for hematological cancers like multiple myeloma.